Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, talks on mitigation strategies for ibrutinib-related cardiac toxicity in patients with Waldenström’s macroglobulinemia. Dr Castillo gives an overview of the cardiac toxicity of ibrutinib, reporting atrial fibrillation as the most common cardiac adverse event (AEs) with a rate of 5-10%, and comments on risk factors for these AEs. Dr Castillo also outlines the management of patients with Waldenström’s macroglobulinemia who are receiving ibrutinib, highlighting the role of the cardiologist, and discusses the importance of minimising the risk of thromboembolic problems and educating patients on these risks. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.